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Selective serotonin reuptake inhibitors and  
congenital malformations
The small risk of harm must be balanced against risk of suboptimal or no treatment
Major depressive disorder in women is most common 
during their childbearing years, and about 13% of 
women in the United States have taken an antidepres‑
sant drug during pregnancy.1 2 In the past 20 years, 
selective serotonin reuptake inhibitors (SSRIs) have 
become a mainstay of treatment in women with major 
depressive disorder; however, concerns persist about 
safety for the developing fetus. This is counterbalanced 
by equally compelling concerns about the consequences 
of undertreatment for mother and child.3
In the linked population based cohort study from 
Denmark, Pedersen and colleagues confirm a previ‑
ously reported doubling of risk for septal heart defects 
after early exposure in pregnancy to SSRIs (odds ratio 
1.99, 95% confidence interval 1.12 to 3.53).4 However, 
in contrast to previous studies, redemptions of prescrip‑
tions for citalopram and sertraline, but not paroxetine 
or fluoxetine, were significantly associated with this 
group of heart defects.5‑8 Furthermore, unlike two pre‑
vious large case‑control studies conducted in the US, 
no association was noted with anencephaly, ompha‑
locele, craniosynostosis, or right ventricular outflow 
tract defects.7 8
Lack of consistency across these studies with respect 
to specific malformations and specific drugs makes it 
difficult to translate the findings into clinical practice. 
One of the fundamental principles of teratology is 
that teratogenic exposures induce specific patterns of 
malformation, and not an increase in the incidence of 
every defect. In other words, if some or all SSRIs are 
teratogenic, we would expect to see similar findings 
for specific drug exposures and specific defects in all 
studies.
One explanation for this inconsistency, assuming that 
SSRIs do cause specific birth defects, is differences in 
study designs. For example, although Pedersen and 
colleagues linked records for 496 881 singleton live 
born infants, they identified only 1370 mothers who 
redeemed multiple prescriptions for an SSRI in the 
perinatal period. Therefore, the study may have been 
insufficiently powered to detect the previously sug‑
gested twofold to threefold increased risk for anenceph‑
aly, omphalocele, craniosynostosis, or right ventricular 
outflow tract defects, all of which occur at least an order 
of magnitude less frequently than septal defects.
Alternatively, these findings could be spurious and 
attributable in observational studies to unmeasured 
or inadequately controlled confounding factors, such 
as maternal obesity, alcohol, tobacco, or periconcep‑
tional use of folic acid supplements; confounding by 
the mother’s underlying condition; or detection bias, 
in which mothers being treated for major depressive 
disorders are more likely to seek out or receive more 
comprehensive prenatal and postnatal testing of their 
children.
How does Pedersen and colleagues’ study contribute 
to clinicians’ and patients’ decisions about the use of 
SSRIs in pregnancy, and how should this be weighed 
against the risks of non‑treatment? The answer remains 
as before—if an increased risk for major congenital mal‑
formations does exist, this study and others suggest that 
the absolute risk for the individual pregnant woman is 
very low. Furthermore, each of the more commonly 
used drugs in this class has been implicated in at least 
one study, so it is difficult to conclude that one SSRI is 
“safer” than another.
We need information from larger studies of specific 
SSRIs, with study designs that control for maternal 
disease type and severity, comorbidities, and other 
exposures. In addition, studies of basic science might 
elucidate the mechanisms involved in inducing specific 
birth defects to support the biological plausibility of a 
causal association.
In August 2009, the American College of Obstetrics 
and Gynecology released a joint statement with the 
American Psychiatric Association on treatment recom‑
mendations for depression during pregnancy.9 Briefly, 
the recommendations state that women with major 
depressive disorder who are contemplating pregnancy 
or who are currently pregnant can start or continue tak‑
ing their drugs. Women who prefer to avoid or discon‑
tinue drugs may benefit from psychotherapy, although 
this will depend on their psychiatric history. Women 
should be informed about the possible risks and ben‑
efits of their treatment choices, and ongoing consulta‑
tion between the patient’s obstetrician and psychiatrist 
is needed during pregnancy, to determine and carry out 
the most appropriate and acceptable treatment plan.
Most drugs taken by pregnant women have not been 
well studied, or studied at all with respect to safety of 
the fetus.10 Although research about SSRIs and preg‑
nancy outcomes is plentiful, it does not necessarily pro‑
vide definitive answers for clinical practice. Clinicians 
and patients need to balance the small risks associated 
with SSRIs against those associated with undertreat‑
ment or no treatment. 
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Thigh circumference and risk of heart disease  
and premature death
The strength of the association needs further research
Several anthropomorphic indices have been devised 
to help clinicians predict cardiovascular risk, including 
body mass index, waist circumference, hip circumfer‑
ence, and waist‑hip ratio. Because none has clearly 
been shown to be superior,1 investigators continue 
to look for better measures, and in the linked study 
Heitmann and Frederiksen propose a new one—thigh 
circumference.2
In a cohort of 1436 men and 1380 women aged 35‑65 
years participating in the Danish MONICA (monitor‑
ing trends in and determinants of cardiovascular dis‑
ease) project, the authors examined the association 
between thigh circumference and the incidence of 
cardiovascular disease and coronary artery disease at 
10 years and total mortality at 12.5 years. They fitted 
four separate proportional hazard regression models 
to the data for either sex to examine the association 
between thigh circumference, measured in centimetres 
directly below the gluteal fold of the right thigh, and 
hazard ratio of disease and death. The model adjusted 
for smoking, education, physical activity, menopause 
(in women), body fat percentage, height, body mass 
index, waist circumference, alcohol intake, systolic 
blood pressure, and concentrations of total cholesterol 
and triglycerides. They used centiles of thigh circum‑
ference and made the 50th centile (equal to 55 cm) 
the base reference (hazard ratio of 1). In most of the 
models they found an almost linear increase in risk as 
thigh circumference dropped below 55 cm, which was 
independent of age or sex; above that circumference, 
risk decreased but showed no consistent relation. They 
concluded that below a threshold of about 60 cm the 
risk of developing heart disease, or dying prematurely, 
was greatly increased.
The results raise several questions. Is this association 
real and independent, or a spurious or chance finding? 
The statistical modelling used in this study was rigor‑
ous—it removed the effects of known conventional risk 
factors and minimised (but did not, and cannot, totally 
eliminate) residual confounding. Unfortunately, with 
regard to coronary heart disease for both sexes and 
cardiovascular disease for women, the hazard ratios 
became non‑significant as more variables were added 
to the models, which may not have happened if the 
sample had been larger.
Is this association biologically plausible? It would 
seem logical that having bigger thighs would be a reflec‑
tion of greater adiposity, and that this would increase 
the risk of heart disease. However, the authors cite stud‑
ies suggesting that too little muscle or subcutaneous fat 
(or both) in the lower limbs may predispose to adverse 
glucose and lipid metabolism. Has the association been 
replicated in other studies? They cite a single study of 
patients with chronic obstructive pulmonary disease in 
whom the mid‑thigh muscle cross‑sectional area was 
a better predictor of mortality than body mass index. 
Interestingly, other studies have shown that larger hip 
circumference (which might be a proxy for thigh cir‑
cumference) significantly reduces the risk of incident 
diabetes and coronary heart disease.3
Will this association help clinicians predict risk in 
individual patients more accurately than they already 
do using readily accessible and validated risk calcula‑
tors? The answer is—we do not know. To improve indi‑
vidual risk estimates beyond those that we can derive 
now, the hazard ratios would need to be much larger 
than those seen in this study. The highest risk equalled 
hazard ratios between 2.0 and 2.5, and these applied 
to only 2.5% of all patients—those with thigh circumfer‑
ences between 46.0 cm and 46.5 cm. A risk predictor is 
potentially useful if people who go on to have an event 
have a higher predicted risk on the basis of the new 
predictor than those who do not have an event. The 
probability of seeing such an increased risk in every 
patient who demonstrates the risk predictor is called 
the c‑statistic, and the higher it is (c‑statistic ≥0.7), the 
more useful the predictor. To achieve such values, the 
strength of association between the risk predictor and 
the risk of disease needs to be high, close to an unad‑
justed hazard ratio of 10 or more.4 Given that the high‑
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est hazard ratio associated with models that were not 
fully adjusted in this study was 4.65, it seems unlikely 
that thigh circumference will be clinically useful.
If a risk prediction model that incorporates thigh cir‑
cumference in addition to other known risk factors is to 
be incorporated into usual practice, we need to ensure 
several things—firstly, that the new model discriminates 
better (has a higher c‑statistic) than existing models; 
secondly, that it is well calibrated—that the predicted 
and observed risk estimates for each stratum of risk 
are similar; and thirdly, that using the new model will 
lead to an appropriate change in intended management 
in more patients now correctly reclassified as having 
higher or lower risk than would be the case using exist‑
ing risk prediction models.
More research is needed to see whether measuring 
the thigh circumference with a tape measure adds any‑
thing more to our clinical management than eliciting 
risk factors from the history, examining the cardiovas‑
cular system, and measuring serum lipids. Randomised 
trials are needed to test whether interventions that 
increase thigh muscle mass through increased physi‑
cal activity—in addition to or separate from current 
primary prevention strategies—decrease cardiovascu‑
lar risk more than current practice. If this approach is 
shown to be effective, the public health implications 
would be intriguing. 
Canoy D. Distribution of body fat and risk of coronary heart disease 1 
in men and women. Curr Opin Cardiol 2008;23:591-8.
Heitmann BL, Frederiksen P. Thigh circumference and risk of heart 2 
disease and premature death: cohort study. BMJ 2009;339:b3292.
Parker ED, Pereira MA, Stevens J, Folsom AR. Association of hip 3 
circumference with incident diabetes and coronary heart disease: 
the Atherosclerosis Risk in Communities study. Am J Epidemiol 
2009;169:837-47.
Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. 4 
Limitations of the odds ratio in gauging the performance of a 
diagnostic, prognostic, or screening marker. Am J Epidemiol  
2004;159:882-90.
can financial incentives improve health equity?
evidence shows that they might, if targeted appropriately
Recently, much interest has been shown in how 
financial incentives can increase health enhancing 
behaviours.1‑3 Two centres are studying the subject—
the Centre for the Study of Incentives in Health (a 
joint initiative between King’s College, Queen Mary, 
and the London School of Economics; www.kcl.ac.uk/
schools/biohealth/research/csincentiveshealth/) and 
the Center for Health Incentives at the University 
of Pennsylvania (www.med.upenn.edu/ldichi/). By 
encouraging healthier behaviours, it is hoped that 
incentives will help to contain healthcare costs and 
improve health. If the incentives motivate people in 
higher socioeconomic groups more than those in lower 
socioeconomic groups, however, they could exacer‑
bate health inequalities. In the linked analysis article, 
Schmidt and colleagues highlight this as a potential 
problem in Germany, where a sickness fund rewards 
people for engaging in preventive activities and for 
minimising use of health care, which might encourage 
the less well off to forgo needed health care.1
These are legitimate concerns, but we should not 
conclude that all incentives harm health equity. Stud‑
ies across a range of interventions have shown that 
people within lower socioeconomic groups do some‑
times respond significantly to incentives. Most of these 
studies were conducted in the United States, but their 
findings should be applicable to other countries.
For example, vouchers redeemable for fruit juice 
significantly increased concentrations of β carotene in 
pregnant women on low incomes.4 This finding con‑
curs with the Organisation for Economic Co‑operation 
and Development’s recent recommendation that cash 
payments or food vouchers should be offered to mate‑
rially deprived pregnant women to boost the take‑up of 
antenatal services.5 Early visits to childhood health cen‑
tres and uptake of vaccinations have been increased by 
financial incentives in Mexico, Nicaragua, Colombia, 
and Jamaica.2 A $10 (£6; €6.8) incentive significantly 
increased the uptake of mammograms in women on 
low incomes aged 40‑64 years.6 Financial incentives 
have also improved participation of intravenous drug 
users in a hepatitis B vaccination programme and a 
tuberculosis treatment programme.7 8 Several other 
examples of the positive effects of financial incentives 
have been published.9 10
These studies show that in some areas of health care 
modest financial incentives can substantially affect the 
behaviours of the relatively poor. Healthcare incentives 
do not always have a positive effect, however, and evi‑
dence of a positive sustained effect on more complex 
lifestyle behaviours, such as smoking or weight loss, is 
lacking.3
Some of the studies may have volunteer bias— 
volunteers may be particularly motivated to change their 
behaviour—and few studies provide adequate information 
on costs, let alone value for money. Moreover, the stud‑
ies do not test the differential effect of incentives on the 
relatively poor versus the better off. Because less wealthy 
people do respond to incentives, health inequalities could 
be reduced if incentives were targeted at them.
Targeting certain groups is controversial because it 
can breed resentment in the untargeted population. This 
can undermine solidarity, a key feature of European 
healthcare systems. Also, should the target be set at 
the family level (for example, families whose income 
is below a certain amount) or the geographical level 
(poor communities)? Because pockets of wealth often 
exist in poor communities, targeting at the family level 
seems the most sensible choice. Targeted interventions 
may be the best option in the current global financial 
climate because they are less expensive than those 
aimed at the population.
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Evidence indicates that appropriately targeted 
incentives could reduce inequalities in health out‑
comes. Ongoing assessment of their affordability, 
effectiveness, cost effectiveness, and unintended con‑
sequences is needed. Irrespective of the effectiveness 
of incentives, some people will argue that they do 
not tackle the root cause of poverty, and that money 
and health behaviours are incommensurate goods.11 
Like all tools, financial incentives may have unfortu‑
nate consequences unless handled with care, but it 
seems premature and irresponsible to exclude them 
c ompletely from the policymaking kitbag.
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Screening for intracranial aneurysms in aDPKD
A more accurate risk assignment model is needed
Autosomal dominant polycystic kidney disease 
(ADPKD) is one of the most common monogenic 
human diseases, with an incidence of 1 in 1000. 
Asymptomatic aneurysms can be detected in 6% of 
patients with ADPKD without a family history, but 
in up to 16% of patients with a family history.1 This 
compares with an estimated prevalence of 1‑2% in the 
general population. Intracranial aneurysm rupture is 
a rare but devastating complication of AKPKD that 
occurs on average 10 years younger than sporadic 
intracranial aneurysms. The youngest reported case 
was a 13 week old infant, and in one study 10% of 
patients were younger than 21 years.2 Intracranial 
aneurysm rupture is associated with a death rate of 
up to 65%. Treatment of a ruptured intracranial aneu‑
rysm by either neurosurgical clipping or endovas‑
cular treatment also carries an unacceptably high 
mortality rate of 8‑10% and morbidity (disability or 
dependency) rate of 16‑21%.3 
The risk of rupture of asymptomatic intracranial 
aneurysms occurring in the general population is 
primarily determined by size, location, and a his‑
tory of rupture.4 For instance, the rate of rupture for 
intracranial aneurysms less than 10 mm in diameter 
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is estimated at 1 in 2000 patient years (0.05% per 
year), but is 10 times higher when a previous rupture 
has been documented.5 Nevertheless, the natural his‑
tory of intracranial aneurysm in ADPKD has been 
uncertain, and it has been reported that aneurysm 
formation and rupture may cluster in families.6 Given 
this uncertainty, which patients should be screened 
for asymptomatic intracranial aneurysms? And can 
we begin to assign a lifetime risk of rupture for each 
ADPKD patient?
Recent studies have shed light on the natural 
history of asymptomatic intracranial aneurysms 
in ADPKD. In one study, 21 patients without a 
history of rupture (66.7% with a positive family 
history) with small (3.5 mm diameter) intracranial 
aneurysms detected by presymptomatic screening 
were followed‑up for a median of seven years.7 No 
ruptures were detected. Only one patient (who had 
a negative family history) had an increase in aneu‑
rysm size and another (who had a positive family 
history) developed a second aneurysm. Another 
prospective study included 20 patients with and 
without a previous rupture.8 Over 15 years, only 
11% of asymptomatic patients initially detected by 
scr eening developed a new aneurysm, however, 
36% presenting with a previous rupture developed 
new ones. In a third study, 76 patients with an 
initial negative scan had a repeat scan after a 
median follow‑up of 9.7 years.9 Of these, 42% had a 
positive family history of intracranial aneurysm rup‑
ture. New ruptures were detected in two patients—
one with, and the other without a positive family 
history.
Although these studies are small with a selection 
bias, the overall conclusion is that the prognosis for 
asymptomatic intracranial aneurysms in ADPKD is 
excellent. The only factor that seemed to correlate 
with the development of new ruptures was a history 
of rupture. The studies also imply that aneurysms 
that are destined to rupture could have a different 
natural history to those that are not going to. This is 
consistent with observations that 50% of intracranial 
aneurysms in ADPKD that rupture are small—that 
is, less than 10 mm.1
Can genetics help us? The two genes mutated 
in ADPKD, PKD‑1 (85%) and PKD‑2 (15%), 
have been identified, and intracranial aneurysms 
occur in patients with both genes. The most 
extensive study to date indicates that different 
ADPKD mutations may confer different risk for a 
vascular phenotype.10 Although no clear relation‑
ship between genotype and phenotype was found 
for PKD‑2, PKD‑1 patients with intracranial aneu‑
rysms were significantly more likely to carry germ‑
line mutations in the 5′ half of the gene compared 
with those without intracranial aneurysms. People 
with a stronger family history—that is, more than 
two first degree relatives who are affected—were 
significantly more likely to carry mutations more 
5′ than those with no family history. Many patients 
with 3′ mutations, however, also had a rupture. This 
means that mutation testing is insufficiently precise 
to assign risk.
Where does this leave us in terms of clinical 
practice? Patients who have had a previous rup‑
ture seem to be at higher risk and need lifelong 
screening. For asymptomatic patients, the presence 
of a strong family history of rupture (at least two 
first degree relatives) remains the best predictor 
of rupture, and a case can be made to screen this 
group.4
Recently, an attempt has been made to quantify 
the probability of intracranial aneurysm rupture 
for individual patients using a Bayesian random 
effects model, which is based on the frequency of 
rupture in each pedigree in the context of family 
size.6 11 This needs to be tested in larger populations 
and refined by including relevant risk factors 
such as previous rupture, the specific ADPKD muta‑
tion, and factors important in sporadic intracranial 
aneurysm rupture—for example, hypertension, 
smoking, and alcohol consumption.4 Nevertheless, 
it is a start to assign individual risk more precisely, 
and hence inform the decision to screen. Overall, 
patients and doctors should be reassured by evi‑
dence from these studies, which does not support 
routine screening in all patients with ADPKD. Until 
a more accurate risk assignment model is available, 
doctors need to explain the balance of benefits and 
harms to patients, and discuss the best course of 
action.12
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The green paper on the future of social care for adults 
was published on 14 July 2009.1 The purpose of Shap-
ing the Future of Care Together is to debate the options 
for the future funding of social care and support for 
two key groups of vulnerable adults: older people and 
younger people with disabilities. In both groups the 
numbers in need of care are substantial and predicted 
to increase.1 About 2.45 million older people have 
some social care needs,2 and 1.2 million receive some 
publicly provided social care services.3
At the heart of the debate is the distinction, 
enshrined in the initial structure of the post war wel‑
fare state, between healthcare needs and social care 
needs and how these should be met. Health needs are 
the province of the NHS, funded mainly from gen‑
eral taxation within the broad structure of a national 
system that is committed to equitable quality and 
access to care. Social care needs were conceptualised 
as separate. Local authorities administer the system 
and organise the nature and extent of social care in 
response to local needs, and they are authorised to 
charge whatever is deemed appropriate.4‑6
Analysis of different forms of welfare provision 
internationally shows that medical care is seen to 
merit special consideration, with care provided free, 
or with users having to pay only a modest contribu‑
tion.7 Even in the United States, where health care 
may be construed as closest to consumer goods, some 
aspects of the system show the special status of medi‑
cal care, such as the Medicare programme for older 
people. This contrasts with social care, which has no 
special status, and where the types of tasks involved—
such as personal care, preparation of meals, or care 
of the house—are part of normal daily life and serv‑
ices that we might be expected to pay for ourselves. 
Indeed, social care is often represented as an area of 
personal responsibility, in contrast to the more collec‑
tive responsibility ascribed to medical care. However, 
these tasks are important in enabling older people to 
continue to live at home independently.8
It has always been presumed that people should 
contribute towards their social care, in the United 
Kingdom and other countries, although the size of 
the contribution may vary. Thus there is an increasing 
distinction between the provision of health care and 
social care based not just on how needs are defined 
and met, but also on how they are paid for. An exam‑
ple of this tension is the funding of long term care.9 
Social care is means tested in England, and any‑
one with assets worth more than £23 500 (€27 300; 
$38 500) who needs to go into a care home receives 
no help from the state. Thus, older people and their 
families can face huge bills for care. The cost of a care 
home is about £24 000 a year and that of a nursing 
home is £35 000.10 Older people (and their families) 
spend around £5.9bn on social care, a figure that 
matches state funding.10 Under the current system, 
some people have to pay as much as £200 000 for 
social care, whereas others receive it free.1
In response to what is termed the “postcode” social 
care lottery, the green paper proposes a national 
social care service to tackle this variability in service 
provision and charging. At the heart of this are the 
proposals for the future funding of social care and 
three national policy options, two of which explicitly 
include some state support for social care. Specifically 
excluded are both fully funded state care (too expen‑
sive) and making people entirely responsible for their 
social care arrangements (too many people would be 
unable to afford such care). In two of the proposals 
the state would contribute a quarter to a third of social 
care costs, with people taking out insurance at a cost 
of £20 000‑£25 000 to cover the remaining costs, or 
paying themselves, with help for those on low income. 
The third option is compulsory insurance against the 
need for social care.
These are important proposals that will shape the 
future of the provision of social care for future gen‑
erations of vulnerable adults. They mark a shift away 
from the inherent variability of the social care system 
towards a nationally based social care system, relating 
to England in the first instance. This is an important 
debate that is currently open to public consultation 
until 13 November (http://www.dh.gov.uk/en/Con‑
sultations/Liveconsultations/DH_102339).
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